Introduction The aim of this study was to evaluate the equianalgesic ratio of transdermal
buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive …

Background: Several myths on buprenorphine's pharmacology exist: possible analgesic
ceiling effect, feasibility of combination with other opioid agonists, and the reversibility of …

Background Buprenorphine is often administered by the transdermal route (transdermal
buprenorphine [TB]) in cancer patients with severe neuropathic pain. However, high doses …

Objective The aim of this preliminary study was to explore the possibility of using higher
doses of transdermal buprenorphine (TD-BUP) than those commonly used and available as …

Objective: The aim of this study was to evaluate the effect and tolerability of low doses of
transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. Methods …

Strong opioids are recommended for treating severe cancer pain in the advanced stages of
the disease. Few data are available concerning the efficacy of buprenorphine in cancer …

Transdermal buprenorphine has been assessed as a therapy for chronic cancer and non-
cancer pain in both clinical and postmarketing surveillance studies. Data from 239 patients …

Objectives Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-
treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or …

Patients with moderate to severe malignancy-related pain frequently require the use of
opioid pharmacotherapy. Unfortunately, many cancer patients continue to be prescribed …

BACKGROUND:: The equipotency ratio of transdermal (TD) fentanyl to oral morphine has
been established as 1: 100; for buprenorphine TD, a ratio of 1: 75 has been proposed …